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ABSTRACT 
Lipophilicity is an important physicochemical parameter of biological relevance; although its in- vivo predictive capability is 
dependent on accuracy and reliability of platforms used for its determination. This work examines biomimetic attribute of 
isocratic chromatographic hydrophobicity index (ICHI), experimental logarithm of octanol – water partition coefficient (LogP) 
and some computed lipophilicity indices for eight (8) selected antipsychotic agents and their predictive capability in drug 
discovery. The retention behavior of 5 first-generation and 3 second-generation antipsychotics was determined on reversed-phase 
chromatographic platform using methanol-phosphate buffer (pH 6.8) mobile phase. The retardation factor obtained was 
transformed to Rm, and plotted against volume fraction of organic modifier in the mobile phase to generate linear graph whose 
x- intercept is ICHI. Experimental LogP values were curled from literature while computed LogP were obtained using respective 
software. The experimentally determined LogPoctanol/water and ICHI were first correlated with index of brain permeability (BBB); 
before all lipophilicity indices were comparatively evaluated and correlated with in-vivo-normalized pharmacokinetic parameters 
curled from literature. ICHI gave better correlation with BBB index (r = 0.976) compared to Log Poctanol/water (r = 0.557). 
Comparative lipophilicity evaluation shows clustered pattern for second generation antipsychotics compared to first generation. 
In vivo correlation was poorer for the 8 drugs (r < 0.7), better with subset of phenothiazine homologues (r = 0.51 to 0.97). The 
ALogP, LogPoctanol/water, cLogP and ICHI gave highest correlation with the pharmacokinetic parameters. The biomimetic attributes 
of ICHI is better than for LogPoctanol/water in predicting brain permeability,  but lower for in-vivo pharmacokinetic prediction. 
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INTRODUCTION 
  
Antipsychotic drugs are a major class of psychotherapeutic 
agents for ameliorating the symptoms of schizophrenia; which 
has been classified as one of the top leading 15 diseases 
responsible for global disease burden and disability (Global 
Disease Burden, 2017).    A variety of typical antipsychotics 
i.e. first generation antipsychotics such as chlorpromazine, 
thioridazine etc. and atypical antipsychotics i.e. second 
generation antipsychotics like clozapine has been used to 
lessen the positive and negative symptoms of schizophrenia 
respectively through blockade of dopaminergic 
neurotransmission in the brain (Bhosale et al., 2014). In order 
to maximize their therapeutic impact, it is critical to control 
the secondary pharmacologic effect  of  these compounds and 
thus their Absorption, Distribution, Metabolism and Excretion 
(ADME) properties by optimizing lipophilicity. Lipophilicity 
is the key critical physico-chemical property that regulates 
ability of antipsychotics to cross the blood brain barrier via  p-
glycoprotein (Loscher, 2005); regulate their gastro-intestinal 
resorption and distribution via the albumin (Varshney et al., 
2010)  and also facilitates their diffusion and hence potency 
(Mikitsh and Chacko, 2014). This makes lipophilicity a vital 
metric in evaluating drug potential during preclinical trials 
(Peruskovic et al., 2014); and could guide optimization of 
potential lead molecules with antipsychotic activity (Nielsen 
and Nielsen, 2009; Hopkins et  al.,  2014; Meanwell, 2016). 
 Lipophilicity is among the three critical physicochemical-
biomimetic parameters, others being kinetic solubility and 
artificial membrane binding; for modeling in vivo drug 
disposition and quality of drug molecules (Gleeson et al., 
2015; Valko, Teague and Pidgeon, 2017). Several 
lipophilicity models such as log octanol-water partition 
coefficient (log P); calculated log P and chromatographic 
hydrophobicity index are useful in biomimetic profiling, 
however with relative limitations. For instance log P and log 
D have been reported unreliable for lipophilicity profiling of 
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whereas chromatographic index e.g. from reversed phase high 
pressure liquid chromatographic platform gives reliable 
estimate (Valko et al., 1997), irrespective of the solubility 
status of the compound (Young et al., 2011). Likewise, 
calculated log P has been reported as “often inaccurate”; and 
can limit the potential of some promising compounds in drug 
discovery (Tsopelas et al., 2017; Giaginis et al., 2018). 
  In vitro-in vivo correlation (IVIVC) is a way of finding a 
good correlation between in vivo results and in vitro data for 
the purpose of optimizing human trials; predictive 
characterization of in vivo pharmacokinetics towards reducing 
need for elaborate bioequivalence studies (Chavda et al., 
2016; Gomeni et al., 2019). Since lipophilicity has been 
reported as vital to determining in vivo pharmacokinetic 
properties (Constantinescu et al., 2019), a reliable model of 
lipophilicity measurement would guarantee a good in vitro-in 
vivo correlation (IVIVC); and is required for harnessing the 
biomimetic attributes of lipophilicity in  future drug discovery 
research  with minimal failure rate. The architecture of the 
blood-brain barrier (BBB), which regulates partitioning of 
drug into the brain is somewhat different from architecture of 
bio-membrane barrier bordering other drug compartments of 
the human body. 
 Morphologically, brain capillaries are like those found in 
other tissues, yet brain vessels are functionally bound to the 
other cells of the brain parenchyma. BBB consists of blood 
vessels built up by specialized endothelial cells (ECs), 
astrocytes, pericytes, and neuronal terminations. Astrocytes 
lay their end-feet over the continuous basal lamina and form a 
very restrictive barrier (Martas et al., 2014). 
 It is therefore reasonable to surmise that what constitute 
biomimetic attributes of lipophilicity estimating platforms 
will vary depending on the intended site of action of a given 
drug, since bio-membrane architecture in different 
compartments of the body is not uniform. Thus, we 
hypothesize that various lipophilicity descriptors will 
correlate differently with index of BBB penetration and 
general pharmacokinetic parameters. 
 This study therefore aims to first, comparatively evaluate 
lipophilicity characterization from these seven descriptors 
obtained from three different platforms i.e. octanol/water 
partitioning, chromatographic and computational algorithms; 
second, assess correlation of the two experimentally 
determined lipophilicity i.e. LogPoctanol/water and ICHI with 
computed blood brain barrier penetration; and third estimate 
the biomimetic attributes of all the lipophilicity indices in 
assessing in vivo pharmacokinetics of antipsychotic agents. 
    
 
MATERIALS AND METHODS 
 
Materials: Methanol (Merck), Liquid paraffin, n-hexane 
(analar, BDH), distilled water, Phosphate buffer pH 6.8, 
Potassium dihydrogen phosphate (BDH, UK), Sodium 
hydroxide (Lobachemie, India), conical flasks, filter paper, 
pipette, measuring cylinder, volumetric flask, TLC tanks, 
precoated aluminum   TLC   plates   GF254   (Merck,   
Germany),   Model   compounds:   first   generation 
antipsychotics:  chlorpromazine  (1),  haloperidol  (2),  
trifluoperazine  (3),  thioridazine  (4), prochlorperazine (5); 
second generation antipsychotics: clozapine (6), olanzapine 
(7), risperidone (8) which are shown in Fig. 1. 
 
Equipment: Ultraviolet lamp (254/365, Gallenkamp, U.K.), 
Drying oven (Astell Hearson PBS 040, England), Hot plate, 
Vacuum pump (Oerlikon Leybold, Germany), Analytical 
weighing balance (Mettler H80, UK), pH meter (PBS 040, 
England), 
 
Chromatographic evaluation: Lipophilicity profiling of the 
model compounds was carried out by reversed phase thin 
layer chromatography on silica gel plates, 5 x 10 cm (Merck, 
Darmstadt Germany) coated with 5% liquid paraffin as 
stationary phase; and phosphate buffer (pH 6.8)  as mobile 
phase. The solutions of the model compounds in methanol 
was spotted onto the plates, air dried and developed by 
ascending order. After development, the plates were air dried 
before the retardation factor (Rf) was determined. All 
measurements were conducted in duplicate and at room 
temperature (33 + 2
o
C). The Rf was transformed to Rm, and 
plotted against the volume fraction of the organic modifier 
for the binary mobile phase to generate a linear relationship 
with the equation below:  
Rm = Rmw  + Sφ 
where φ is the volume of organic modifier fraction, S is the 
slope and indicates the rate of solute partitioning into the 
aqueous phase while Rmw is the intercept and value of Rm 
extrapolated to pure water (0 % methanol) as the mobile 
phase.  The lipophilicity index used for this study is φ0 
known as isocratic chromatographic hydrophobicity index 
(ICHI); a derived parameter obtained when Rm equals zero 
i.e. x-intercept of the linear regression; and obtained from the 
equation: 
φ0 = -Rmw/S 
 
Calculations: Apart from the logarithm of octanol-water 
partition coefficient (logPoctanol/water) curled from pubchem 
database (www.pubchem.ncbi.nlm.nih.gov), five other 
lipophilicity indices were calculated  with  two  online-
available  software  algorithms  ALOPS  2.1  
(www.vcclabs.org), SwissADME SwissADME 
(www.swissadme.ch) and a commercially available software 
Bio-Loom (www.biobyte.com). The index for blood-brain 
barrier (BBB) penetration was calculated with molsoft drug-
likeness and molecular property prediction software 
(www.molsoft.com) while the Statistical evaluation of the 
chromatographic linear regression; correlation analysis of the 
two experimentally based lipophilicity index i.e. log Po/w and 
ICHI with BBB index; and of all the lipophilicity descriptors 
with the pharmacokinetic parameters were performed by 
GraphPad Prism Version 7 (SanDiego, CA). 
 
Pharmacokinetic Parameters: The bioavailability of the 
drug depicted by Area under Curve (AUC∞), maximum 
plasma concentration (Cmax) and time for maximum 
concentration (Tmax) for single dose oral administration of 
the selected drugs were curled from literature. The AUC∞ 






Figure. 1:  
Chemical structures of antipsychotic compounds studied. The blue oval highlights the phenothiazine heterocycle in compounds 
1, 3, 4 & 5. 
 
RESULTS AND DISCUSSION 
 
Chromatographic lipophilicity determination: The linear 
regression of the Rm against the organic modifier fraction of 
the mobile phase (ϕ) for the antipsychotic agents is 
represented in Fig. 2. The regression parameters for this 
chromatographic evaluation of the compound’s lipophilicity 
are also summarized in Table 1. 
 The Rm values decreased linearly with increasing 
concentration of the organic modifier in the mobile phase (“r” 
ranges from 0.967 to 0.997). The extrapolation of the values 
to the x-axis i.e. 50 % methanol fraction or Rm = zero; gives 
the φ0 which is known as the isocratic chromatographic 
hydrophobicity index (ICHI). ICHI reflects the relative 
partitioning between the hydrophobic stationary and 
hydrophilic mobile phase based on the equation: 
Rm = Rmw + Sφ; where φ = organic modifier fraction, 
 
at Rm = 0, φ0 = - Rmw/S 
 
Correlation of the experimentally determined lipophilicity 
indices with computed Blood Brain 
 
Barrier penetration index: The association between the 
experimental lipophilicity indices and the index of brain 
permeability is described in Fig. 3 below. 
Chromatographically generated ICHI gave higher positive 
correlation with BBB index (r = 0.976) while log Poctanol/water 
gave a poorer positive correlation (0.557) reflecting that ICHI 
could predict therapeutic availability of these drugs in the 








Linear regression of Rm versus volume fraction of the organic modifier (methanol) 
 
Table 1:  
Linear regression parameters for the chromatographic estimation of the antipsychotics’ lipophilicity showing ICHI, r, Sy.x residual 
and the equation Rm = Rmw + Sφ 
Compound name ϕ0 (ICHI) r Sy.x Equation 
Chlorpromazine 1.140 0.986 0.0288 Rm = -1.86ϕ + 2.13 
Haloperidol 0.723 0.973 0.0881 Rm = -3.57ϕ + 2.58 
Trifluoperazine 0.979 0.979 0.0838 Rm = -3.85ϕ + 3.77 
Thioridazine 1.310 0.980 0.0242 Rm = -1.3ϕ + 1.69 
Prochlorperazine 1.070 0.994 0.0248 Rm = -2.48ϕ + 2.66 
Clozapine 0.919 0.967 0.1330 Rm = -2.8ϕ + 2.57 
Olanzepine 1.100 0.970 0.0778 Rm = -1.47ϕ + 1.62 
Risperidone 0.109 0.997 0.0385 Rm = -9.41ϕ + 1.02 
 
 
Figure 3:  
Correlation of experimentally determined lipophilicity descriptors – (a) Log Poctanol water and (b) ICHI on liquid paraffin 
film – with computed brain permeability index. 
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Figure 4:    
Graphical visualization of the various   lipophilicity indices   for the selected antipsychotic compounds 
 
 
Table 3:   
Correlation of Pharmacokinetic  Parameters  with  lipophilicity  descriptors  for  the selected 8 compounds 
 ICHI LogP cLogP ALogP MLogP WLogP XLogP3 
AUC -0.286 -0.704 -0.65 -0.558 -0.444 -0.58 -0.191 
Cmax -0.564 -0.24 -0.282 -0.4 -0.0123 -0.052 -0.0277 
Tmax 0.27 -0.0171 -0.061 0.0502 -0.293 -0.164 -0.26 
 
Table  4:   
Correlation of Pharmacokinetic  Parameters  with  lipophilicity  descriptors  for  the compound 1 to 5 
 ICHI LogP cLogP ALogP MLogP WLogP XLogP3 
AUC 0.633 0.726 0.739 0.694 0.752 0.563 0.543 
Cmax 0.708 0.782 0.789 0.763 0.756 0.556 0.503 
Tmax -0.889 -0.964 -0.964 -0.971 -0.873 -0.745 -0.598 
 
Evaluation of the  different  lipophilicity  descriptors  and  
their  association  with  important Predicted ADME 
properties relevant for antipsychotic activity: The seven  
different  lipophilicity descriptors  comprised  of  
experimentally determined  ICHI, LogP octanol-water and 
computer-generated logP values i.e. cLogP, ALogP, MLogP, 
WLogP and XLogP3 are summarized in Table 2 below. 
 The graphical visualization of the various lipophilicity 
descriptors is represented in Fig. 4.  All the computed logP 
values for the compounds except compound 5 are closely 
clustered with the log Poctanol/water unlike with ICHI (which is a 
non-logarithmic metric) except for compound 5 which could 
be due to presence of significant contribution of the oxygen 
hetero atom in the salt on the overall atomic effect captured by 
the XLogP3algorithm. However, all the lipophilicity indices 
were closely clustered from compound 6 to 8; which could be 
due to similarity in evaluation of the hydrogen bond 
acceptance capacity of these molecules by the different models 
(Šegan et al., 2017). 
 Correlation between the different lipophilicity indices and 
the experimentally determined pharmacokinetic data gave 
different pattern that showcases the variability in the model 
algorithms. All the lipophilicity descriptors gave poor negative 
correlation (i.e. r < 0.9) with the pharmacokinetic parameters 
except poor positive correlations between ICHI, ALogP with 
Tmax, and  XLogP3  with  Cmax  (Table  3).  However, by 
restricting the correlation analysis to compounds 1 to 5; which 
are the first generation antipsychotic agents led to significant 
increase in the correlation coefficient in which all the 
lipophilicity descriptors had a negative association with the 




Table  5:   
Correlation of  Pharmacokinetic  Parameters  with  lipophilicity  descriptors  for  the compounds with phenothiazine ring (i.e. 
compounds 1, 3, 4, and 5) 
 ICHI LogP cLogP ALogP MLogP WLogP XLogP3 
AUC 0.908 0.932 0.912 0.97 0.76 0.547 0.543 
Cmax 0.895 0.909 0.888 0.954 0.733 0.521 0.51 
Tmax -0.689 -0.915 -0.927 -0.923 -0.986 -0.897 -0.9 
 
Finally, correlation within the phenothiazine compounds i.e. 
chlorpromazine, trifluoperazine, thioridazine and 
prochlorperazine gave the highest correlation coefficients in 
which ALogP had the best correlation with AUC and Cmax (r 
= 0.97 and 0.954) respectively while MLogP had best but 
negative correlation (r = -0.986) with the Tmax (Table 5).   
This underscores that determination of associations within 
homologous series give higher correlation coefficient since 
there is less variability in the topological and molecular 
features of the compounds (Hau et al., 1999; Xuefeng et al., 
2006). Thus, establishing a functional relationship   for   
predicting   in   vivo   pharmacokinetics   based   on   
lipophilicity   as   the physicochemical parameter is weakened 
by the large chemical diversity of the selected library of 
compound s (Dambolena et al., 2016); which is reflected in the 
pattern of correlation seen from Table  3  to  Table  5.  The 
AUC  and  Cmax  were  positively  correlated  with  the  
lipophilicity descriptors unlike the Tmax, since higher 
lipophilicity leads to faster absorption and peak level, hence 
lower Tmax (Ballas and Dinges, 2009; Paul, 2019). Overall, 
of the five computational algorithms, cLogP and ALogP gave 
relatively high correlation coefficient, comparable to the 
experimentally determined logP indices i.e. ICHI and LogP; 
and underscores why these two are among the most widely 
used algorithms for log P predictions (Souza et al., 2011). 
 In conclusion, lipophilicity plays an important role in the 
pharmacodynamics and pharmacokinetics of antipsychotic 
agents; and must be carefully determined with an appropriate 
model during drug discovery phase to optimize therapeutic 
value. The ICHI is a better predictor of blood brain 
permeability, which is a critical parameter in antipsychotic 
efficacy, compared to the LogPoctanol/water.  In terms of in-
vivo  pharmacokinetic  prediction,  this  study  shows  that  
prediction accuracy is improved within the homologous 
congeners; and the best predictive accuracy was observed with 
the following sequence: ALogP > LogP > cLogP > ICHI. 
Further study using larger sample size would prove the relative 
merits of these four parameters in predicting pharmacokinetic 
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